Literature DB >> 26355710

Diverse expression patterns of the EMT suppressor grainyhead-like 2 (GRHL2) in normal and tumour tissues.

Sabine Riethdorf1, Sabrina Frey1, Sonja Santjer1, Malgorzata Stoupiec1, Benjamin Otto2, Lutz Riethdorf3, Christina Koop4, Waldemar Wilczak4, Ronald Simon4, Guido Sauter4, Klaus Pantel1, Volker Assmann1.   

Abstract

The transcription factor grainyhead-like 2 (GRHL2) plays a crucial role in various developmental processes. Although GRHL2 recently has attracted considerable interest in that it could be identified as a novel suppressor of the epithelial-to-mesenchymal transition, evidence is emerging that GRHL2 also exhibits tumour-promoting activities. Aim of the present study therefore was to help defining the relevance of GRHL2 for human cancers by performing a comprehensive immunohistochemical analysis of GRHL2 expression in normal (n = 608) and (n = 3,143) tumour tissues using tissue microarrays. Consistent with its accepted role in epithelial morphogenesis, GRHL2 expression preferentially but not exclusively was observed in epithelial cells. Regenerative and proliferating epithelial cells with stem cell features showed a strong GRHL2 expression. Highly complex GRHL2 expression patterns indicative of both reduced and elevated GRHL2 expression in tumours, possibly reflecting potential tumour-suppressing as well as oncogenic functions of GRHL2 in distinct human tumours, were observed. A dysregulation of GRHL2 expression for the first time was found in tumours of non-epithelial origin (e.g., astrocytomas, melanomas). We also report GRHL2 copy number gains which, however, did not necessarily translate into increased GRHL2 expression levels in cancer cells. Results obtained by meta-analysis of gene expression microarray data in conjunction with functional assays demonstrating a direct regulation of HER3 expression further point to a potential therapeutic relevance of GRHL2 in ovarian cancer. Hopefully, the results presented in this study may pave the way for a better understanding of the yet largely unknown function of GRHL2 in the initiation, progression and also therapy of cancers.
© 2015 UICC.

Entities:  

Keywords:  EMT; GRHL2; HER3; chemoresistance; gene amplification

Mesh:

Substances:

Year:  2015        PMID: 26355710     DOI: 10.1002/ijc.29841

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

Review 1.  Roles of Grainyhead-like transcription factors in cancer.

Authors:  S M Frisch; J C Farris; P M Pifer
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

2.  Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.

Authors:  Adnen Faddaoui; Razan Sheta; Magdalena Bachvarova; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Stephane Gobeil; Chantale Morin; Karim Ghani; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2017-02-22       Impact factor: 4.534

Review 3.  Grainyhead-like transcription factors in cancer - Focus on recent developments.

Authors:  Grzegorz Kotarba; Agnieszka Taracha-Wisniewska; Tomasz Wilanowski
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-02

4.  Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.

Authors:  Christin Gasch; Theresa Oldopp; Oliver Mauermann; Tobias M Gorges; Antje Andreas; Cornelia Coith; Volkmar Müller; Tanja Fehm; Wolfgang Janni; Klaus Pantel; Sabine Riethdorf
Journal:  Mol Oncol       Date:  2016-07-22       Impact factor: 6.603

Review 5.  Grainyhead-like 2 as a double-edged sword in development and cancer.

Authors:  Jiaxing He; Chunyang Feng; He Zhu; Shuying Wu; Peng Jin; Tianmin Xu
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

6.  MicroRNA 122, Regulated by GRLH2, Protects Livers of Mice and Patients From Ethanol-Induced Liver Disease.

Authors:  Abhishek Satishchandran; Aditya Ambade; Sitara Rao; Ying-Chao Hsueh; Arvin Iracheta-Vellve; David Tornai; Patrick Lowe; Benedek Gyongyosi; Jia Li; Donna Catalano; Li Zhong; Karen Kodys; Jun Xie; Shashi Bala; Guangping Gao; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2017-10-04       Impact factor: 22.682

7.  Moesin (MSN) as a Novel Proteome-Based Diagnostic Marker for Early Detection of Invasive Bladder Urothelial Carcinoma in Liquid-Based Cytology.

Authors:  Jeong Hwan Park; Cheol Lee; Dohyun Han; Jae Seok Lee; Kyung Min Lee; Min Ji Song; Kwangsoo Kim; Heonyi Lee; Kyung Chul Moon; Youngsoo Kim; Minsun Jung; Ji Hye Moon; Hyebin Lee; Han Suk Ryu
Journal:  Cancers (Basel)       Date:  2020-04-21       Impact factor: 6.639

8.  GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification.

Authors:  Vin Yee Chung; Tuan Zea Tan; Ming Tan; Meng Kang Wong; Kuee Theng Kuay; Zhe Yang; Jieru Ye; Julius Muller; Cheryl M Koh; Ernesto Guccione; Jean Paul Thiery; Ruby Yun-Ju Huang
Journal:  Sci Rep       Date:  2016-02-18       Impact factor: 4.379

9.  Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium.

Authors:  Carl Fishwick; Janet Higgins; Lawrence Percival-Alwyn; Arianna Hustler; Joanna Pearson; Sarah Bastkowski; Simon Moxon; David Swarbreck; Chris D Greenman; Jennifer Southgate
Journal:  Cell Death Differ       Date:  2017-03-10       Impact factor: 15.828

10.  Epithelial-Mesenchymal Transition: Role in Cancer Progression and the Perspectives of Antitumor Treatment.

Authors:  A V Gaponova; S Rodin; A A Mazina; P V Volchkov
Journal:  Acta Naturae       Date:  2020 Jul-Sep       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.